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ABSTRACT
The most abundant populations of non-neoplastic cells in the glioblastoma (GBM) 
microenvironment are resident microglia, macrophages and infiltrating monocytes 
from the blood circulation. The mechanisms by which monocytes infiltrate into 
GBM, their fate following infiltration, and their role in GBM growth are not known. 
Here we tested the hypothesis that loss of the fractalkine receptor CX3CR1 in 
microglia and monocytes would affect gliomagenesis. Deletion of Cx3cr1  from the 
microenvironment resulted in increased tumor incidence and shorter survival times 
in glioma-bearing mice. Loss of Cx3cr1 did not affect accumulation of microglia/
macrophages in peri-tumoral areas, but instead indirectly promoted the trafficking 
of CD11b+CD45hiCX3CR1lowLy-6ChiLy-6G-F4/80-/low circulating inflammatory monocytes 
into the CNS, resulting in their increased accumulation in the perivascular area. Cx3cr1-
deficient microglia/macrophages and monocytes demonstrated upregulation of IL1β 
expression that was inversely proportional to Cx3cr1 gene dosage. The Proneural 
subgroup of the TCGA GBM patient dataset with high IL1β expression showed shorter 
survival compared to patients with low IL1β. IL1β promoted tumor growth and 
increased the cancer stem cell phenotype in murine and human Proneural glioma 
stem cells (GSCs). IL1β activated the p38 MAPK signaling pathway and expression of 
monocyte chemoattractant protein (MCP-1/CCL2) by tumor cells. Loss of Cx3cr1 in 
microglia in a monocyte-free environment had no impact on tumor growth and did not 
alter microglial migration. These data suggest that enhancing signaling to CX3CR1 or 
inhibiting IL1β signaling in intra-tumoral macrophages can be considered as potential 
strategies to decrease the tumor-promoting effects of monocytes in Proneural GBM.
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INTRODUCTION
The glioma subtype known as glioblastoma (GBM) 
is the most aggressive and most common primary brain 
tumor. Despite research advances, over 95% of patients 
succumb to their disease, resulting in a median survival 
time of only 14.6 months [1]. These dismal survival 
statistics highlight the urgent need for new approaches to 
GBM therapy. Analysis through The Cancer Genome Atlas 
(TCGA) initiative identified several subclasses of GBM, 
termed Proneural, Neural, Classical, and Mesenchymal, 
which are strongly associated with genomic abnormalities 
in platelet-derived growth factor receptor (PDGFR), 
isocitrate dehydrogenase 1 or 2 (IDH 1 or 2), epidermal 
growth factor receptor (EGFR), and neurofibromin 
1 (NF1), respectively [2, 3]. Although initial studies 
showed that patients with a Proneural subtype had 
markedly better survival compared to the other subtypes 
[4], this phenomenon was conferred when glioma-CpG 
island methylator phenotype G-CIMP-positive tumors 
were excluded [5]. Differences among the subtypes 
are highlighted by the fact that they show differential 
responses to glioma cell-targeted standard therapies 
of various intensities, with better results achieved by 
more intense therapeutic regimes in all subtypes except 
Proneural [3]. 
Histological analysis of GBM revealed a 
heterogeneous cellular composition of neoplastic glioma 
cells and non-neoplastic cells, which form a tumor 
microenvironment composed of brain-resident microglia, 
infiltrating monocytes/macrophages, reactive astrocytes, 
endothelial cells, pericytes, neural stem/progenitor cells, 
and other immune cell infiltrates [6, 7]. Microglia and 
monocytes/macrophages constitute up to 30% of tumor 
mass in both human and murine GBM [7]. It has been 
demonstrated that microglia promote tumor growth [8], but 
to what extent tumor promotion is attributable to microglia 
versus monocytes/macrophages still remains unclear. It is 
also unclear to what extent GBM macrophages are derived 
from infiltrating cells from the blood circulation and what 
the ratio between microglia and monocyte/macrophages 
is. The importance of a nuanced understanding of the 
roles of microglia and monocyte/macrophages in GBM is 
highlighted by studies showing that these two cell types 
have dramatically different responses to injury [9, 10]. 
In addition to the invasive growth that prevents a 
complete surgical resection, the resistance of GBM to 
therapy is partially explained by two hallmark features of 
glioma stem cells (GSCs): radio-resistance and chemo-
resistance. Experimentally, these cells can be enriched 
based on expression of a variety of surface markers [11, 
12] or their ability to exclude Hoechst dye or DyeCycle 
violet (DCV) in a side population assay (SP) [13, 14]. 
GSCs reside in the perivascular area (PVA) in both human 
and murine gliomas [15, 16.] Thus, understanding the ways 
that microglia and infiltrating monocytes/macrophages 
interact with GSCs in the PVA may help to identify new 
therapeutic targets in the glioma microenvironment that 
can be combined with standard glioma therapies. 
To study the role of microglia and monocytes/
macrophages in GBM and their potential interactions 
with GSCs, we perturbed macrophage activation in 
tumors by genetically inactivating the CX3CR1/CX3CL1 
signaling pathway. CX3CR1 is expressed by monocytes 
in the circulation and exclusively by microglia in the 
central nervous system (CNS) [17]. The ligand CX3CL1 
is expressed by neurons and is the most abundantly 
expressed chemokine in the CNS. Accordingly, CX3CR1 
regulates communications between neurons and microglia. 
The effects of CX3CR1 signaling on disease progression 
vary depending on the type of the CNS disease [18-21]. 
To study the functional role of CX3CR1/CX3CL1 
signaling in GBM, we used a genetically engineered 
mouse model (GEMM) of adult PDGFB-driven gliomas, 
which is based on RCAS/Tv-a, a somatic cell-specific 
gene transfer system [22]. In terms of both gross pathology 
[23] and molecular profile, these tumors strongly 
resemble the human Proneural GBM subtype, which 
represents 30% of human GBM [3, 4]. As these mice 
are immunocompetent, this model is a suitable system 
to study interactions between immune and glioma cells. 
Here, we show that loss of CX3CR1/CX3CL1 signaling 
in tumor-associated microglia and monocytes results in 
an increased incidence of GBM formation with shorter 
tumor latency in glioma-bearing mice. While having no 
effect on microglial migration in peri-tumoral regions, 
loss of Cx3cr1 did increase Ly-6Chi “inflammatory” 
monocyte infiltration from the blood circulation into 
GBM, where they preferentially localized in perivascular 
areas. Loss of Cx3cr1 results in a dose-dependent increase 
in IL1β expression in microglia and macrophages. This 
overexpression of IL1β in turn promotes glioma growth, 
induces activation of the p38 MAPK pathway, increases 
the GSC phenotype, and upregulates CCL2 expression, 
which correlates with greater monocyte infiltration. These 
data suggest that CX3CL1/CX3CR1 signaling, which is 
the most active chemokine-signaling system in the healthy 
CNS and is not expressed by GBM cells, may have 
potential as a therapeutic strategy to decrease monocyte 
infiltration into GBM. Our findings also imply that IL1β 
may be a therapeutic target for human Proneural GBM 
patients. 
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RESULTS
Cx3cr1 deficiency results in increased tumor 
incidence and shorter survival times in GBM-
bearing mice
Microglia and monocyte infiltration and function 
are partially regulated by chemokines, which act on 
chemokine receptors such as CX3CR1. As CX3CR1 
signaling has been implicated in both microglial activation 
and migration, we decided to study the role of CX3CR1 in 
gliomagenesis. For these studies, we used mice in which 
the Cx3cr1 gene was inactivated following germline 
insertion of the green fluorescent protein (GFP) gene, such 
that heterozygous mice Cx3cr1GFP/+ expressed the GFP 
reporter in cells that retained receptor function, whereas 
homozygous Cx3cr1GFP/GFP cells were labeled with GFP 
but lacked Cx3cr1expression (i.e. Cx3cr1GFP/GFP equals 
Cx3cr1-/-) [24]. We transplanted freshly dissociated cells 
from GBM generated in Gli-luciferase;Nestin-Tv-a;Ink4-
Arf-/-;pten fl/fl (referred to as NiG mice) into B6 (strain 
control or Cx3cr1+/+), Cx3cr1GFP/+ and Cx3cr1GFP/GFP 
Figure 1: Homozygous deletion of Cx3Cr1 in the tumor microenvironment increases the percentage of GBM formation 
and shortens tumor latency. This leads to an increase in the total number of macrophages in tumors, which mainly accumulate in 
perivascular regions of GBM. A) Kaplan-Meier survival curves show that homozygous loss of Cx3cr1 results in shortened survival of 
tumor-bearing mice compared to heterozygous loss of Cx3cr1 or B6 mice (Cx3cr1GFP/GFP vs. Cx3cr1GFP/+ MC p=0.0520, GBW *P < 0.05; 
Cx3cr1GFP/GFP vs. B6 MC *P < 0.05, GBW **P<0.01; Log-rank (Mantel-Cox-MC) tests and Gehan-Breslow-Wilcoxon tests (GBW) were 
used). The tumor incidence (%) and median survival of tumor-bearing mice in Cx3cr1 homozygous, heterozygous knock-in and B6 mice 
are incorporated in the curves (n=13, 10, 23 for B6, Cx3cr1GFP/+ and Cx3cr1GFP/GFP, correspondingly). B) Representative BLI images of 
tumor-bearing mice and quantification of BLI in Cx3cr1 homozygous, heterozygous knock-in and B6 mice at the end-point of survival 
curves showing no statistically significant differences in tumor size based on Cx3Cr1 status. C) Brain tumor sections from B6, Cx3cr1GFP/+ 
and Cx3cr1GFP/GFP mice with GFP (green), anti-Iba1 (red), and anti-CD31 (gray) and counterstained with DAPI (blue). Representative 
images demonstrate that Cx3cr1GFP/GFP animals exhibit a higher number of Iba1-positive cells, which are mainly localized in perivascular 
areas of tumors. D) The number of Iba1-positive cells and perivascular areas were quantified in tumors from the three genotypes (n=5 
animals per each genotype; left and right graph, correspondingly). Loss of two copies of Cx3cr1 resulted in a statistically significant 
increase in the number of Iba1-positive cells and increased PVN area compared to the loss of one copy or wild-type (*p < 0.05), E) which 
reside in perivascular areas of GBM (one-way ANOVA with Tukey’s multiple comparisons test, *p < 0.05 and **p < 0.01, respectively).
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mice. Homozygous loss of Cx3cr1 resulted in a significant 
decrease in tumor latency and in increased tumor incidence 
(Fig. 1A). A trend toward increased tumor incidence was 
also observed in heterozygous GBM-bearing mice (Fig. 
1A). The survival curve summarizes the tumor incidence 
and median survival times of tumor-bearing mice from 
the three different genotypes. Next we evaluated whether 
the shorter survival times of tumor-bearing mice in the 
Cx3cr1-deficient background might result from tumor 
location or size at the end-point of survival. All tumor-
bearing mice independent of background demonstrated 
similar neurological signs including lethargy, grooming, 
and weight loss of 15% or more, which were used as 
criteria to determine the end-point. As transplanted tumor 
cells also had a Gli-luciferase reporter, we visualized 
tumors by BLI during tumor growth (data not shown) and 
at the end-point of survival in vivo and ex vivo. The size 
of tumors generated in B6, Cx3cr1GFP/+ and Cx3cr1GFP/
GFP, as determined by BLI, was not significantly different 
between groups (Fig. 1B). Ex vivo BLI imaging of tumor-
containing whole brains also showed no significant 
differences in tumor location in the three genotypes (data 
not shown). 
CX3CL1 expression is decreased in both murine 
and human GBM tissue
CX3CL1 was abundantly expressed in naïve brains 
of NiG mice, while mRNA expression was significantly 
less in murine GBM samples and freshly sorted GBM 
cells (Fig. S1A). Assessment of REMBRANDT data also 
revealed that CX3CL1 mean expression intensity was 
decreased in human GBM samples compared to non-
tumor control samples (Fig. S1D). CX3CL1 protein was 
abundantly expressed in naïve brain but was undetectable 
in GBM tissue, freshly sorted or cultured GBM cells (Fig. 
S1B and S1C). These data suggest that tumor cells do not 
express detectable levels of CX3CL1 protein and that 
mRNA levels are low compared to the naïve brain, which 
could be partially attributable to the known phenomenon 
of significantly decreased numbers of neurons in GBM 
tissue. 
In gliomas, Cx3cr1 deficiency increases density of 
microglia/macrophages, which are preferentially 
localized in perivascular areas
CX3CR1 signaling is implicated in the survival 
of microglia and monocytes/macrophages. We thus 
determined the effect of CX3CR1 deficiency on 
macrophage density in GBM. Quantification of CX3CR1 
(based on GFP-expression) and ionized calcium-binding 
adapter molecule 1 (Iba1) double-positive cells from 
tumors generated in Cx3cr1GFP/+ and Cx3cr1GFP/GFP mice 
revealed that over 95% of CX3CR-positive cells were 
also positive for Iba1 (data not shown, Fig. 1C). Based 
on these data, we then used Iba1 to quantify the density of 
macrophages in tumors generated in the three genotypes. 
Homozygous loss of Cx3cr1 resulted in a statistically 
significant increase in the density of macrophages 
in tumors (Fig. 1C and 1D). Iba1/CX3CR1 double-
positive cells were mainly located in the PVA (Fig. 1C). 
Quantification of PVA, based on area occupied by Iba1-
positive cells, in tumors generated in the three genotypes 
demonstrated statistically significant increases in the sizes 
of PVA due to increased area occupied by macrophages in 
GBM in Cx3cr1-deficient hosts (Fig. 1E). There were no 
genotype-dependent differences in either total vessel area 
or average vessel size in either tumors or the surrounding 
brain tissue (Fig S2A and S2B). These data suggest that 
the increases in PVA and the number of macrophages 
observed in tumors from Cx3cr1GFP/GFP mice are not due 
to increased angiogenesis. 
Cx3cr1 deficiency results in a significant increase 
in Ly-6Chi “inflammatory” monocyte infiltration 
into GBM
Increased density of macrophages in stromal 
Cx3cr1-deficient tumors can be caused by either local 
expansion of microglia or by increased infiltration 
of monocytes from the blood circulation, possibly 
accompanied by expansion of this population. To test 
for increased monocyte density, we analyzed CD11b 
and CD45 expression in similar-sized tumors at the end-
point of survival in each of the three genotypes using 
flow cytometry. Previously, characterization of tumor-
associated microglia and macrophages by flow cytometry 
identified that, although both resident microglia and 
blood macrophages have high CD11b expression, they 
show differential expression levels for the CD45 surface 
antigen, with microglia being low and blood macrophages 
being high [25, 26]. After setting the total CD45+CD11b+ 
population to 100%, we then examined differences in 
the percentages of CD45hi (hematogenous) cells versus 
CD45low cells (microglia) (Fig. 2A). While there were 
no significant differences observed in the percentage of 
CD45hi cells in CX3CR1-negative tumors (Fig. 2B), we 
found a significant enrichment of CD11b+ CD45hi Ly-6Chi 
Ly-6G- F4/80-/low immature or inflammatory monocytes in 
tumors generated in Cx3cr1-deficient mice as compared to 
tumors in heterozygous Cx3cr1 or wild-type (WT) mice 
(Fig. 2C). This population was CX3CR1low as previously 
reported [31]. Ly-6G staining confirmed the monocytic 
lineage of these cells and also showed that there were no 
genotype-dependent differences in neutrophil infiltration 
(Fig. 2D). Next, we evaluated whether the phenomenon 
of increased monocyte infiltration is also observed in 
the brains of naïve Cx3cr1-deficient mice compared 
to heterozygous Cx3cr1 or WT mice. There were no 
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significant differences in the percentages of CD45hi or 
infiltrating monocytes in Cx3cr1-deficient mice compared 
to heterozygous Cx3cr1 or WT mice (Fig. S3), suggesting 
that this is GBM-specific. Taken together, these data 
in Figures 1 and 2 show increased GBM infiltration by 
inflammatory monocytes and a higher density of tumor-
associated macrophages in mice lacking CX3CR1. 
To test whether the local proliferation of monocytes, 
macrophages and microglia contributes to their increased 
accumulation in PVA, we performed a BrdU incorporation 
experiment with two pulses every 6 hours (at 10 mg/
kg body weight) for 12 hours before sacrificing tumor-
bearing animals of the three genotypes and quantifying 
Iba1+BrdU+ cell numbers. We did observe small but 
significant differences in the proliferation rates of Iba1-
positive cells between tumors generated in WT (B6) and 
Cx3cr1-deficient mice (Cx3cr1GFP/GFP  mice) (Fig. 3A 
and 3B). Next we examined whether decreased levels 
of apoptosis of Iba1+ cells in PVA could contribute 
to their increased numbers in tumors generated in 
Cx3cr1-deficient mice. We stained tumors from the 
three genotypes for cleaved-caspase-3 and Iba1. We did 
not observe significant differences in cleaved-caspase-
3+BrdU+ cell numbers in any of the three genotypes (Fig. 
3C and 3D). Next we analyzed whether the amount of 
Ly-6Chi monocytes in the blood changes over the course 
of disease progression in host Cx3cr1-deficient tumor-
bearing mice, potentially contributing to their increased 
density in tumors. The number of CD11bv Ly-6ChiLy-
6G- inflammatory monocytes in the blood was analyzed 
before mice were subjected to stereotactic surgeries for 
tumor cell transplantation and then blood collection was 
repeated 20 days post-surgery, when mice did not yet show 
signs of tumors. The density of inflammatory monocytes, 
however, was significantly decreased in Cx3cr1-deficient 
mice with tumors (Fig. 3E), a decrease which might be 
Figure 2: Loss of Cx3Cr1 results in a significant increase of Ly-6Chi “inflammatory” monocyte infiltration into GBM. 
A) Representative dot plots that are gated on CD11b+CD45+ cells, with red and green circles defining CD11b+CD45hi (blood-derived 
macrophages) and CD11+CD45lo/int (resident brain microglia). Total population of CD11b+CD45+ is considered as 100%, and they are 
further gated on Ly-6C and F40/80 positivity for tumors from the three genotypes (upper panel). The CD45+CD11b+ population is further 
gated for Ly-6C and Ly-6G positivity to distinguish monocytes from neutrophils and further gated for GFP (CX3CR1), which shows that 
while inflammatory monocytes are positive for GFP, neutrophils are negative. B) Dot plots represent the percentage of CD45hi population 
in the total CD11b+CD45+ population of tumors from the three genotypes. Although there is a trend towards an increase in CD45hi in tumors 
from Cx3cr1GFP/GFP mice, it does not reach statistical significance (n=4, 8 and 5 individual tumors for B6, Cx3cr1GFP+ and Cx3cr1GFP/GFP, 
respectively). Tumor sizes were chosen close to the end-point of survival to ensure similar sizes in the three different genotypes. C) Dot 
plots represent the percentage of Ly-6Chi monocytes in the total CD11b+CD45+ population in tumors from the three different genotypes 
(each dot corresponds to one animal). A one-way ANOVA with Tukey’s multiple comparisons test was performed and demonstrated that 
there was a statistically significant increase in the percentage of Ly-6Chi monocytes in tumors from Cx3cr1GFP/GFP animals compared to B6 
or Cx3cr1GFP+ animals (*p < 0.05 and **p < 0.01, correspondingly). D) Dot plots represent the percentage of Ly-6G+ neutrophils in tumors 
from the three different genotypes showing that loss of one or both copies of Cx3cr1 had no impact on neutrophil infiltration into GBM. 
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caused by increased infiltration into the CNS. In end-
point of survival experiments, all mice showed decreases 
in inflammatory monocytes as compared to their original 
blood levels (data not shown) and there were no significant 
differences between groups (Fig. 3F). These data suggest 
that the increased density of inflammatory monocytes in 
Cx3Cr1-deficient mice is due to their increased infiltration 
into the CNS from the blood circulation during disease 
progression. 
Figure 3: The increased number of inflammatory monocytes in Cx3cr1-deficient background is due to their increased 
infiltration from the blood and not to local proliferation or decreased cell death. A) Representative images of brain tumor 
sections from B6, Cx3cr1GFP+ and Cx3cr1GFP/GFP mice were stained with anti-Iba1 (green), anti-BrdU (red), and counterstained with nuclear 
DAPI (blue). B) Quantified bar graphs from A showing that there was no statistically significant difference in the number of BrdU+Iba1+ 
cells in tumors from the three different genotypes. C) Representative images of brain tumor sections from B6, Cx3cr1GFP+ and Cx3cr1GFP/
GFP mice were stained with anti-Iba1 (green), anti-Cleaved Caspase-3 (red), and counterstained with nuclear DAPI (blue). D) Quantified 
bar graphs from C showing that there was no statistically significant difference in the number of BrdU+ Cleaved Caspase-3+ cells in 
tumors from the three different genotypes. For B and D, one-way ANOVAs with Tukey’s multiple comparisons tests were performed and 
demonstrated that there were no statistically significant differences observed in the number of BrdU+Iba1+ and BrdU+ Cleaved Caspase-3+ 
cells in the three genotypes. E) Dot plots representing the number of CD11b+Ly-6Chi Ly-6G- inflammatory monocytes were analyzed from 
the blood of the same mice before and 20 days after tumor cell transplantation. There was a significant decrease in Ly6Chi inflammatory 
monocytes in Cx3cr1GFP/GFP mice, suggesting increased infiltration to GBM. F) Dot plots represent the number of CD11b+Ly-6Chi Ly-
6G- inflammatory monocytes when mice were sacrificed at the end-point of survival. There was a significant difference in CD11b+Ly-6Chi 
Ly-6G- inflammatory monocytes when the three genotypes were compared and they all showed a reduction compared to naïve mice before 
the transplant, see E. A paired t-test was used in Figure 6E and a one-way ANOVA with Tukey’s multiple comparisons test was performed 
for F. Scale bars for A and C represent 50μm.
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Loss of Cx3cr1 leads to a dose-dependent increase 
in IL1β expression by microglia/macrophages
To gain insight into the tumor-promoting effects of 
CX3CR1-deficient cells in the tumor microenvironment, 
the expression levels of TNF-α, iNOS, IL6 and IL1β, 
which each have altered expression due to loss of 
CX3CR1 in different CNS diseases [18, 20], were 
examined by quantitative RT-PCR. CD11b+CD45+Ly-6G- 
and CD11b+CD45+Ly-6G-GFP+ cells were sorted from 
tumors generated in B6, Cx3cr1GFP/+ and Cx3cr1GFP/GFP 
mice, correspondingly; RNA was isolated and analyzed 
for TNF-α, iNOS, IL6, and IL1β expression. While no 
significant changes were observed between the three 
genotypes for TNF-α, iNOS, or IL6 by qPCR (Fig. 4A), 
we confirmed a significant dose-dependent increase (when 
one or both copies of the Cx3cr1 gene were removed) 
in IL1β expression. We excluded the possibility of 
constitutive differences in IL1β expression in naïve brains 
from the three different genotypes (Fig. 4B). We analyzed 
the TCGA data set [2] for relative IL1β mRNA expression 
in human GBM subgroups (Fig. 4C), as our murine 
tumors strongly resemble the human Proneural GBM 
subtype, and found that the Proneural group with high 
IL1β expression showed significant survival differences 
compared to patients with Proneural tumors with low IL1β 
expression (Fig. 4D). IL1β expression was not associated 
with survival in the other GBM subtypes. 
IL1β increases glioma cell growth/viability and 
enhances the glioma stem cell phenotype
Next we examined whether IL1β can promote 
tumor growth in our murine Proneural GBM model. We 
generated primary cultures from PDGFB-driven gliomas 
generated in NiG mice. Freshly isolated tumor cells were 
cultured in two different conditions: the first condition was 
chosen to enrich for GSCs (serum-free neural stem cell 
medium supplemented with EGF and bFGF), while the 
second condition was chosen to enrich the main/bulk tumor 
population (10% FBS in DMEM medium). We performed 
MTT assays for the dose response to recombinant IL1β 
and showed that the most effective dose for growth was 
100pM (data not shown). While 24h incubation with IL1β 
showed significant increases in growth/viability in GSC-
enriching conditions (Fig. 5B, left panel), IL1β mediated 
no growth advantage for cells cultured in FBS-containing 
medium (Fig. 5B, right panel). These data suggest that 
IL1β signaling selectively affects cells grown in GSC-
enriching conditions. Next we evaluated IL1R1 expression 
and showed that both mRNA and protein are expressed 
in GBM cells (Fig. S4A and S4B). In response to IL1β 
binding to IL1R1, a complex sequence of combinatorial 
phosphorylation and ubiquitination events results in 
activation of nuclear factor κB (NF-κB) signaling and the 
JNK and p38 mitogen-activated protein kinase pathways, 
which cooperatively induce the expression of canonical 
Figure 4: Loss of Cx3cr1  results in a dose-dependent increase in IL1β expression by CX3CR1-positive cells. IL1β 
expression is up-regulated in human GBM and levels of expression correlate with Proneural patient survival. A) Relative mRNA expression 
dot plots from freshly FACS-sorted CD11b+CD45+CX3CR1+ cells from the three genotypes showed no differences in TNF-α, iNOS or IL6 
levels, B) while a significant dose-dependent increase was observed in IL1β expression levels. All samples were normalized to the mRNA 
levels of β-actin and are presented as fold-change compare to naïve brains. A one-way ANOVA with Tukey’s multiple comparisons test was 
performed and demonstrated that there was a statistically significant dose-dependent increase in IL1β expression (*p < 0.05 (Cx3cr1GFP) 
and **p < 0.001(Cx3cr1GFP/GFP) compared to B6). C) Relative IL1β mRNA expression in the four GBM subtypes of the TCGA data set. 
A Newman-Keuls multiple comparisons test was used (****p < 0.0001; n=118, 75, 139, 128 for Proneural, Neural, Mesenchymal and 
Classical, respectively). D) Kaplan-Meier survival curves for the Proneural, Neural, Mesenchymal and Classical subtypes. High and Low 
are defined as +/- 1 Standard Deviation for each subtype. Log-rank (Mantel-Cox-MC) tests and Gehan-Breslow-Wilcoxon tests (GBW) 
were used to determine p values. The only significant difference in survival was observed in Proneural patients (*p < 0.05 MC and **p < 
0.01 GBW).
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IL1β target genes (such as IL-6, CXCL8, CCL2, COX-2, 
IκBα, IL1α, IL1β, MKP-1) via transcriptional and post-
translational modifications (see detailed discussion in 
review [27]). Next we examined what downstream targets 
were activated in response to IL1β treatment in GSCs. 
IL1β treatment induced activation of the p38 MAPK 
pathway in all four mouse GSC lines tested, but not 
extracellular signal-regulated kinase (ERK) (Fig. 5C, Fig. 
S5). p38 MAPK has been shown to play important roles in 
glioma invasion, progression and therapy resistance [28]. 
CCL2 has been reported to be one of the canonical IL1β 
target genes and is a known chemoattractant ligand for 
Figure 5: IL1β treatment increases glioma cell growth/viability, activates p38/JNK and NF-κB pathways in GSC-
enriching medium, and leads to activation of CCL2 expression. A) Illustration of the steps for the MTT assay. B) Quantification 
of the MTT assay performed on GBM spheres, which were cultured in NSC (left) or 10% FBS (right) with or without IL1β 24h later. These 
data show that while there was no significant increase in the growth in FBS, there was a significant difference in NSC conditions. We used 
three independent primary tumors to derive three independent glioma lines for two conditions. Blue squares show the growth of the original 
tumor and they are connected to red squares that represent the growth in response to IL1β; values on the graphs represent fold increase 
in growth/viability in response to IL1β compare to control growth. An unpaired t-test was used to determine the fold change compare to 
control, * p < 0.05, 95% CI (1,33; 1,69). C) Immunoblot analysis was performed to examine the p38 MAPK, JNK and ERK1/2 signaling 
pathways 0, 10, 30 and 60 minutes after 100pM IL1β treatment. The Western blots shown were performed on the GBM 1 and GBM 2 lines 
(cultured in Geltrex). Similar results were obtained on GBM sphere 3. D) Relative mRNA expression dot plots for CCL2 from glioma cells 
cultured in different conditions with or without 100pM IL1β treatment, showing that IL1β treatment significantly increased CCL2 mRNA 
expression, independent of culture conditions. E) The CCL2 protein levels measured by ELISA in the supernatant showed an increase in 
response to 100pM IL1β treatment. F) Relative mRNA expression dot plots for CCR2 expression from different cell types showing that 
CCR2 was not expressed in cultured glioma cells when grown in NSC conditions. A one-way ANOVA with Tukey’s multiple comparisons 
test was performed, ***p < 0.001 G) The right graph shows correlation with linear regression from 110 proneural GBM samples for IL1β 
and CCL2 RNA expression from the TCGA database. A statistically significant positive correlation was found between IL1β and CCL2 
RNA expression r=0.63, p<0.0001. Linear regression R2=0.4397, p < 0.001.The left graph shows correlation with linear regression from 
40 murine PDGF-B-driven GBM samples for IL1β and CCL2 RNA expression. A statistically significant positive correlation was found 
between IL1β and CCL2 RNA expression r=0.68, p<0.001. Linear regression R2=0.4617, p < 0.001.
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the CCR2 receptor, which is expressed in inflammatory 
monocytes and has been shown to be important for exit of 
monocytes from the bone marrow to the blood circulation 
and subsequent trafficking into the site of inflammation 
[29]. Next we examined whether CCL2 is upregulated 
by IL1β treatment in cultured glioma cells. There was 
significant upregulation of CCL2 mRNA (Fig. 5D) and 
protein expression levels (Fig. 5E) independent of culture 
conditions, whereas CCR2 was preferentially expressed 
by inflammatory monocytes and macrophages (Fig. 5F). 
Since our data showed that IL1β regulates CCL2 mRNA 
expression in glioma cells, we examined whether there was 
a correlation between IL1β and CCL2 mRNA expression 
levels in human GBM subtypes (from TCGA database) 
and murine GBM. We observed a statistically significant 
positive linear association between IL1β and CCL2 mRNA 
Figure 6: IL1β treatment enhances a stem cell phenotype in vitro, which correlates with Cx3Cr1 loss in vivo. A) SP 
analysis of freshly dissociated tumor cells cultured in 10% FBS medium, in NSC medium as spheres, and cultured in NSC medium like 
monolayer. Cells were treated with or without 100pM IL1β for 24h. The right graph shows relative SP from three independent glioma lines 
in three different conditions. B) qPCR data for relative mRNA expression of Nanog, Oct4, Sox2, CD44 and Musashi in GBM cells cultured 
in NSC medium with geltrex as a monolayer. Data represent average value of three independent cell lines. Error bars represent SD. *p < 
0.05 by unpaired t-test. C) SP analysis of GBM samples generated in B6, Cx3cr1GFP+ and Cx3cr1GFP/GFP mice. Inserts show FTC-treated 
samples. The right graph represents relative SP from for 4 independent tumors per genotype.
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expression levels both in human Proneural and murine 
GBM (Fig. 5G). There was a significant positive linear 
association in the Classical subtype, but not in the Neural 
and Mesenchymal subtypes (Fig. S6). Together, these 
data help explain the increased inflammatory monocyte 
infiltration into GBM generated in the Cx3cr1-deficient 
background. Since Cx3cr1-deficient inflammatory 
monocytes and monocyte-derived macrophages express 
higher levels of IL1β compared to heterozygous Cx3cr1 
and WT tumors, they induce increases in CCL2 expression 
by glioma cells, which in turn causes the recruitment 
of more CCR2-positive inflammatory monocytes into 
the tumor, as shown in Fig. 2A and 2B. IL1β from 
inflammatory monocytes has a paracrine effect on glioma 
cells and induces increased levels of CCL2 in tumor cells, 
which in turn has a paracrine effect on inflammatory 
monocytes, resulting in increased infiltration. 
Cx3cr1 loss via increased expression of IL1β leads 
to an enhanced glioma stem cell phenotype in vitro 
and in vivo
We observed an increase in PVA, where glioma stem 
cells are localized, in host Cx3cr1-deficient tumors. We 
therefore examined whether IL1β-treated glioma cells that 
were maintained in GSC-enriching medium would show 
an increase in the glioma stem cell population in vitro. 
We used the SP assay, which is a well-accepted method 
of identifying glioma stem cells in murine and human 
models. Freshly isolated cells from tumors were cultured 
in two different conditions, GSC-enriching conditions and 
the main/bulk-enriching (10% FBS in DMEM medium) 
Figure 7: Cx3cr1 deficiency has no impact on microglial accumulation at the close edge of GBM and has no impact 
on tumor growth in organotypic slice cultures. A) Representative images of Iba1 staining in tumors from the three genotypes. The 
white broken-lines in the images are drawn to show the close and distant edge of the tumors (170 μm each) and DAPI-positive nuclear 
density was used as guide to separate the tumor from the peri-tumoral area. B) Quantified bar graphs for the entire peri-tumoral areas 
that were constructed from a series of 20x images that cover the entire peri-tumoral area (n=7, 6, 7 for B6, Cx3cr1GFP+ and Cx3cr1GFP/GFP, 
correspondingly). C) Quantification of tumor areas in organotypic brain slice cultures from the three genotypes at 6 days post-tumor cell 
inoculation are presented as dot plots. D) Representative images of GFP-positive cells from slices generated from Cx3cr1GFP+ and Cx3cr1GFP/
GFP mice. The white lines in the images are drawn to show the inner and outer layers of the tumors (80 μm each). The quantified numbers 
of GFP-positive cells in the inside, inner and outer layer of tumors are presented as dot blots. A one-way ANOVA with Tukey’s multiple 
comparisons test was performed and demonstrated that there were no statistically significant differences observed in tumor volumes in the 
three genotypes (C and D). Scale bar represents 50 μm for A and 150 μm for D.
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condition. IL1β significantly increased the percentage 
of SP cells in three independent tumor-derived primary 
cells in GSC-enriching medium, while no increase was 
observed in cells that were cultured in serum (Fig. 6A). 
Therefore, we tested whether IL1β treatment could induce 
expression of stem-like cell markers. Nanog and Oct4 
expression were increased, whereas Sox2 expression 
levels were not increased (Fig. 6B). This observation is 
attributable to the fact that Sox2 is both a GSC marker 
and is also associated with the Proneural molecular 
subtype in human [30], so its expression can be extended 
beyond GSCs in mouse tumors as well (data not shown). 
CD44 and Musashi expression were not increased (Fig. 
6B). Together, these data suggest that monocytes and 
macrophages can drive elements of a stem cell phenotype 
in PDGFB-induced gliomas via IL1β expression. 
It was also of interest to determine whether the 
effect of IL1β on the glioma stem cell phenotype occurs 
in human GSCs. In view of our finding that high IL1β 
expression correlated with poor survival only in human 
Proneural GBM, we treated two human Proneural GBM 
GSCs with human IL1β for two weeks. By using a 
limited dilution assay, we showed that self-renewal of 
both GSCs7-11 and 827 [31, 32] were increased by IL1β 
compared to control (Fig. S7).
To confirm whether this effect of IL1β on the stem 
cell phenotype is Cx3cr1-dependent, we analyzed tumors 
generated in B6, Cx3cr1GFP/+ and Cx3cr1GFP/GFP mice at the 
end-points of survival. We observed large variability in the 
% SP (7-45%) in tumors from all three genotypes, which 
was associated with the time of survival of tumor-bearing 
mice. We normalized SP from tumors in Cx3cr1GFP/+ and 
Cx3cr1GFP/GFP mice to B6 tumors based on the time of 
tumor development and represented it as relative SP, which 
was much higher in tumors from Cx3cr1GFP/GFP compared 
to Cx3cr1GFP/+ and B6 (Fig. 6C). These data suggest that 
the in vitro effects of IL1β on stemness are driven by 
Cx3cr1 deficiency in vivo. Since it has been shown that 
increased SP in gliomas correlates with unregulated CD44 
expression and radiation resistance in the same murine 
GBM model, we examined whether CD44 expression is 
increased in PVA area when tumors from Cx3cr1GFP/GFP 
mice are compared to Cx3cr1GFP/+ and B6. We did observe 
an increase in CD44-positive areas in tumors generated in 
Cx3cr1GFP/GFP mice compared to Cx3cr1GFP/+ and B6 (Fig. 
S8).
Loss of Cx3cr1 has no impact on microglia/
macrophage accumulation in peri-tumoral areas 
or on tumor growth in organotypic slice cultures 
Loss of one copy of the Cx3cr1 gene has been 
shown to reduce accumulation of microglia (by 50%) 
and delay optic nerve glioma development [33]. Thus we 
decided to evaluate microglia/macrophage accumulation 
in peri-tumoral areas in tumors from the three genotypes 
by quantifying the total number of Iba1+ cells in two 
concentric peri-tumoral layers of tissue (Fig. 7A and 7B). 
There were no significant differences in the numbers of 
Iba1+ cells in the first and second peri-tumoral layers in 
GBM tissue from B6 and Cx3cr1GFP/+ mice compared to 
the tumors in Cx3cr1GFP/GFP mice. These data suggest that 
loss of Cx3cr1 does not affect accumulation of microglia 
in peri-tumoral areas. In order to assess the functional 
consequences of CX3CR1 deficiency on microglial 
migration and the effect it has on tumor growth, we 
generated gliomas ex vivo in naïve organotypic slice 
cultures generated from B6, Cx3cr1GFP/+ and Cx3cr1GFP/GFP 
mice as described in Supplemental Figure 9. This method 
allowed us to investigate the role of microglial CX3CR1 
on tumor growth. There were no significant differences in 
the size of the tumors at 6 days post-tumor cell inoculation. 
Next, we fixed the organotypic slices, sectioned them into 
8μm sections, and quantified GFP+ microglial density 
in tumors generated ex vivo in slices from the three 
genotypes. Quantification of GFP+ microglia inside of 
the tumor and inner and outer peri-tumoral areas showed 
no significant differences in microglia density whether 
one or two copies of Cx3cr1 were deleted. These data 
suggest that the effect of Cx3cr1 loss on tumor growth and 
increased stem cell-like cell phenotype in vivo is driven by 
increased infiltration of inflammatory monocytes and their 
increased expression of IL1β. 
DISCUSSION
In recent years, accumulating evidence from several 
tumor types has shown the importance of non-neoplastic 
cells in the tumor microenvironment for the maintenance 
of cancer growth and response to therapy. In gliomas, 
microglia and macrophages together represent the most 
abundant non-neoplastic cell types, which are present 
in both low- and high-grade gliomas. While in low-
grade gliomas, the main population of macrophages is 
resident brain microglia [33], we show here that in high-
grade gliomas, one finds a mixture of resident microglia, 
inflammatory monocytes and macrophages. Over the last 
decade, our knowledge of the role of microglia in gliomas 
has evolved significantly [8], but we have yet to determine 
the mechanism by which bone marrow-derived monocytes 
infiltrate into GBM, their fate following infiltration, or 
their role in GBM growth and how different they are 
from microglia. These are all valid questions considering 
major differences in the origin and life span of these 
cells. Monocytes are myeloid-derived cells that belong 
to the mononuclear phagocyte system. They arise from 
hematopoietic stem cells in the bone marrow, are released 
into the bloodstream, and colonize peripheral organs in 
normal and inflammatory conditions [34], where they 
differentiate into macrophages or dendritic cells and have 
multiple functions in homeostasis and innate and acquired 
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immunity. Microglia, on the other hand, originate from 
yolk sac progenitors that migrate into the brain in the early 
stages of development (E10.5) and are maintained locally 
via self-renewal [35]. 
In this study we abrogated CX3CR1/CX3CL1 
signaling in both microglia and inflammatory 
monocytes and studied the effects on glioma growth 
and on the behavior of both cell populations. First, we 
showed that the loss of CX3CR1 signaling in the host 
microenvironment results in increased GBM formation 
and shortened tumor latency. One correlative study 
showed that single nucleotide polymorphisms (SNPs 
heterozygous-CX3CR1-I249) in the human Cx3cr1 gene 
resulted in decreased microglial infiltration and longer 
survival of GBM patients that underwent surgery [36], 
although, whether the post-surgery tissue contained 
inflammatory monocytes or only microglia was not 
investigated. Further studies are warranted to investigate 
the role of the CX3CR1-I249 polymorphism based on 
genetic subtypes of glioma. Another report using GL261 
murine glioma cells demonstrated that loss of Cx3cr1 
in the host microenvironment has only a slight effect on 
survival of tumor-bearing mice and no differences were 
observed in the density of tumor-infiltrated immune cells 
or microglial accumulation [37]. These differences can 
be partially explained by differences in the properties of 
glioma cells that have been used in transplant experiments. 
In contrast to the GL261 model, data from the experiments 
using GEMM of low-grade gliomas showed that decreased 
expression of CX3CR1 resulted in delayed tumor growth 
and decreased accumulation of microglia in tumors; 
most importantly the authors reported that over 95% of 
macrophages in low-grade gliomas are microglia [33]. 
Differences in all the above-mentioned studies and our 
current study show that the role of CX3CR1/CX3CL1 can 
vary depending on the grade and subtype of glioma. This 
can be partially attributed to the fact that GBM subtypes 
show activation of different core signaling pathways. 
Further studies are warranted to determine whether 
monocyte infiltration also occurs in other GBM subtypes. 
Here we demonstrated that loss of Cx3cr1 in the host 
microenvironment resulted in increased accumulation of 
bone marrow-derived Ly6-Chigh “inflammatory” monocytes 
in GBM, in contrast to microglia in low-grade gliomas. 
Our finding of increased monocyte infiltration as 
a result of Cx3cr1 loss in GBM shows similarity with 
recent data in myelorestoration, where the CX3CR1/
CX3CL1 axis controls the release of Ly-6Chigh monocytes 
from marrow such that in Cx3cr1GFP/GFP mice, Ly-6C 
high monocytes accumulated less rapidly in the marrow 
but recovered faster in the blood, resulting in more 
accumulation into the spleen [38]. Increased inflammatory 
monocyte accumulation in GBM as a result of Cx3cr1 loss 
is further supported by data showing that human CX3CL1 
(also known as fractalkine) antagonizes transendothelial 
migration and chemotaxis of freshly isolated human 
monocytes induced by CCL2. Our PDGFB-driven murine 
GBM significantly up-regulated levels of CCL2 mRNA 
and protein expression (unpublished data from our 
laboratory). This would help explain the fact that tumor 
cells up-regulate CCL2 to attract monocyte infiltration 
into GBM, while on the other hand they do not express 
CX3CL1. Increased monocyte infiltration as a result 
of Cx3cr1 loss in our GBM model is further supported 
by a study showing formation of leaky and immature 
microvessels lacking CX3CR1-positive smooth muscle-
like cells, extracellular collagen, and basement membrane 
laminin in Cx3cr1GFP/GFP but not in Cx3cr1GFP/+ mice, when 
matrigel plugs were implanted [39]. We also demonstrated 
that loss of CX3CR1 results in dose-dependent increases 
in IL1β expression, which in turn upregulates CCL2 
expression and recruits more monocytes. Thus when 
the loss of Cx3cr1 resulted in further increases in 
CCL2 expression, we observed greater “inflammatory” 
monocyte infiltration into GBM, mainly localizing in the 
PVA. Similar results with increased IL1β resulting from 
loss of Cx3cr1 were shown in two Alzheimer’s disease 
mouse models and other CNS diseases [18, 20]. IL1β 
was also shown to increase the self-renewal of intestinal 
epithelial stem cells [40]. Recently, we have demonstrated 
the existence and complexity of the PVA in the PDGF 
subgroup of human gliomas and in our PDGF-driven 
mouse gliomas. The PVA of PDGF-driven human and 
mouse gliomas is a complex structure, which contains a 
treatment-resistant, nestin-positive cancer stem-like cell 
population [16]. In gliomas, it has been shown that IL1β 
in combination with TGFβ increases the neurosphere-
forming ability and tumorigenicity of the LN-229 glioma 
cell line, although the mechanism was not elucidated [41]. 
Our data demonstrate that IL1β in GSCs induces activation 
of p38 MAPK and enhances the GSC phenotype in vitro 
and in vivo, which seems to be Cx3cr1-dependent. These 
effects of IL1β can partially explain the tumor-promoting 
effect of CX3CR1 in our mouse model of GBM. In human 
GBM, high expression of IL1β was also correlated with 
shorter survival only in Proneural GBM patients. IL1β 
treatment also increases the stem cell frequency in two 
proneural human GSC lines. Only in Proneural and murine 
GBM did we observe significant positive correlations 
between expression levels of CCL2 and IL1β.
Our data demonstrate that while increasing 
monocyte infiltration and tumor-promoting effects, 
loss of Cx3cr1 has no impact on microglia/macrophage 
accumulation in peri-tumoral areas in vivo or in 
organotypic slice cultures of gliomas ex vivo. The use of 
organotypic slice cultures allowed us to generate gliomas 
in a monocyte-free environment, where we demonstrated 
that loss of Cx3cr1 in microglia had no impact on glioma 
growth. These results suggest that the tumor-promoting 
effect produced by the loss of Cx3cr1 is a result of 
infiltrating inflammatory monocytes from the blood 
circulation. This observation is further supported by data 
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showing that loss of Cx3cr1 has no impact on infiltration 
of other immune cells from the blood, which include 
neutrophils and dendritic cells (DCs). Though it has 
previously been proposed that CNS DCs can arise from 
transformed microglia in vitro in which microglia up-
regulate CD11c in the presence of GM-CSF [42], in our 
GBM model we did not observe up-regulation of CD11c 
in microglia or in the bone marrow-derived CD45hiCD11b+ 
population. 
Taken together, our results provide insights into 
the differences in CX3CR1 signaling in microglia versus 
bone marrow-derived “inflammatory” monocytes, 
which includes migration and tumor-promoting effects. 
In light of these data, the terms “Tumor-associated 
macrophages (TAMs)” that are widely used in the glioma 
literature should be used very carefully, as this is a highly 
heterogeneous population that includes resident brain 
microglia, infiltrating blood monocytes, and macrophages, 
showing very different functions. Based on our data, 
CX3CR1 signaling has differential functions in bone 
marrow-derived inflammatory monocytes versus resident 
microglia. These data also confer the importance of 
studying the biology of inflammatory monocytes in the 
context of GBM as well as the molecules that they secrete 
to promote tumor growth. IL1β is one example that we 
identified in these studies, but this is likely only one of 
many remaining to be identified. 
MATERIALS AND METHODS
Mice
Animals were housed in the Cleveland Clinic 
Biological Resource Unit. All experimental procedures 
were approved by the Institutional Animal Care and 
Use Committee of the Cleveland Clinic (Animal 
Protocol 2013-1029). Mice (6-10 weeks old) were used 
in all experiments. We used age and sex as criteria to 
equally distribute mice from different genotypes for 
all experiments. Gli-Luciferase; Nestin-tv-a;Ink4a-
Arf−/−;ptenfl/fl mice were generated as previously described. 
Cx3cr1GFP+, Cx3cr1GFP/GFP mice were generated from 
heterozygous breeding pairs, backcrossed for more than 
10 generations to B6 [24]. 
Cell cultures and transfection
DF-1 cells were purchased from ATCC, Manassas, 
VA. Cells were grown at 39oC according to instructions 
from ATCC. Transfections with RCAS-PDGFB-HA, 
RCAS-PDGFB-SV40-RFP and RCAS-CRE were 
performed using a Fugene 6 transfection kit (Roche, 
Mannheim, Germany) according to manufacturer’s 
instructions. Transfection efficacies were assessed by 
Western blotting and PCR. 
Generation of tumors
Transgenic mice (Gli-Luciferase; Nestin-tv-a;Ink4a-
Arf−/−;ptenfl/fl referred to as NiG) were anesthetized with 
intraperitoneal injections of a mixture of ketamine 
(0.1 mg/g) and xylazine (0.02 mg/g). One microliter of 
4X104 cell suspension containing either RCAS-PDGF-
B-HA or RCAS-PDGFB-RFP + RCAS-Cre transfected 
(1:1 ratio) DF1 cells was delivered using a 30-gauge 
needle attached to a Hamilton syringe and stereotactic 
fixation device (Stoelting, Wood Dale, IL). Locations 
were determined according to a mouse brain atlas [43]. 
Cells were injected into the right frontal striatum with the 
following coordinates from bregma: AP (anterior) 1.0 mm, 
ML (medial/lateral) 1.0 mm, and DV (dorsal/ventral) 2.0 
mm. Mice were monitored carefully and were sacrificed if 
they displayed lethargy or head tilt due to tumor burden. 
Orthotopic glioma generation
The same procedure was used as described above, 
except 2.5X104 of freshly-dissociated tumor cells were 
injected into the frontal striatum of recipient animals. 
Two or three tumors were used for obtaining single cells 
for orthotopic glioma generation in B6, Cx3cr1GFP+, and 
Cx3cr1GFP/GFP. The GBM grade of donor tumors was 
validated by H&E staining. The tumor cell injections 
into B6, Cx3cr1GFP+, and Cx3cr1GFP/GFP recipients were 
performed on the same day with the same cells. 
Bioluminescence imaging (BLI)
Mice were anesthetized with 3% isoflurane and 
hair covering the head was shaved before retro-orbital 
injection with 75mg/kg body weight of D-luciferin (30mg 
luciferin/ml dH2O at 2.5 μl per gram mouse weight). 
One minute after injection of D-luciferin, images were 
acquired for 8 min with an IVIS 100 (Xenogen) imaging 
system. A photographic image was taken onto which the 
pseudocolor image representing the spatial distribution 
of photon count was projected. A circular region (1.4cm 
diameter) of interest (ROI) covering the tumor region was 
defined and used to quantify the bioluminescent signals in 
all experiments. All representative images were formatted 
using the same maximum and minimum threshold 
parameters. 
Tissue processing
Animals were anesthetized with a mixture 
of ketamine (0.15 mg/g) and xylazine (0.02 mg/g), 
perfused with ice-cold Ringer’s solution, and sacrificed. 
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Brains were removed and processed according to 
the different applications. For H&E validation and 
immunohistochemistry, brains were fixed in 10% neutral 
buffered formalin for 72 hours at RT, processed in a 
tissue processer (Leica, Wetzlar, Germany), embedded 
in paraffin, sectioned (5 μm), and slide-mounted. For 
immunofluorescent staining, brains were fixed in 4% 
PFA overnight at 4°C, sunk in 30% sucrose (dissolved in 
PBS) for 48 hours at 4°C, embedded in Optimal Cutting 
Temperature (OCT, Tissue-Tek, Torrance, CA) compound, 
sectioned (8 μm), slide-mounted, and stored at -80°C.
Immunoflurescent staining (IF)
5 μm and 8 μm coronal sections were used for 
paraffin-embedded and frozen sections in all histological 
studies. The following antibodies were used at the stated 
dilutions: rabbit polyclonal anti-Iba1, 1:100 (Wako Pure 
Chemicals, Osaka Japan); rabbit polyclonal anti-GFP, 
1:100 (Life Technologies, Grand Island, NY); rabbit 
polyclonal anti-Olig2, 1:250 (Chemicon, Temecula 
CA); mouse monoclonal anti-PCNA, 1:2000 (DAKO, 
Glostrup, Denmark); and rat monoclonal anti-CD31, 
1:100 (Dianova, Germany), rabbit polyclonal cleaved 
caspase 3, 1:100 (Cell signaling, Danvers, MA), rat anti-
BrdU, 1:100 (BIO-RAD, Hercules, CA). For IF staining, 
secondary antibodies conjugated to different Alexa-Fluor 
dyes (488 nm, 555 nm, 647 nm from Life Technologies, 
Grand Island, NY) at a dilution of 1:500 in PBS/2% BSA 
were applied. For nuclear counterstaining, DAPI was used 
(Sigma-Aldrich, St. Louis, MO). 
BrdU incorporation
At the end point of survival, tumor-bearing mice 
were given i.p. two pulses every 6 hours (at 10 mg/kg 
body weight, Sigma-Aldrich, St. Louis, MO) for 12 hours 
before they were sacrificed. 
Quantification of IF
For quantification of Iba1-positive cells and CD31 
staining (Fig. 3), five to ten images (20x) of perivascular 
regions were taken per mouse brain using CD31 staining 
as a reference. The total numbers of Iba1-positive cells as 
well as CD31-positive areas were assessed using ImageJ. 
For Iba1-positive cell quantification in peri-tumoral 
areas (Fig. 6), adjacent 10x images (1600 x 1200 pixels, 
300 dpi) were taken and recomposed using Photoshop 
software (Adobe System Incorporated); an outline of the 
tumor border was then determined by DAPI staining and 
two layers (200 pixels or 240 μm width) outside of this 
border were then determined and named as the inner and 
outer layers. Cell numbers were counted with ImageJ and 
normalized to a 1600 x 200 pixel area (1360x170 μm2). 
Flow cytometry
For FACS analysis, brains were digested in 0.25% 
Trypsin/EDTA without phenol red at 37°C for 10 minutes 
(GBM) or 30 minutes (naïve brains, without cerebellum). 
Digestion was stopped by adding 2 volumes of RPMI 
medium containing 10% FBS. Cells were passed through 
a 40 μm cell strainer, centrifuged and resuspended in 30% 
Percoll (GE Healthcare, Princeton, NJ) solution, and laid 
above a 70% Percoll layer (diluted in RPM medium with 
1% FBS). Cells were separated by centrifuging at 800xg 
for 30 minutes at 4°C. Cells from the 30%/70% Percoll 
interphases were collected and washed with FACS buffer 
(DPBS with 0.5% BSA) and blocked with 100 μl of 2x 
blocking solution (2% FBS, 5% normal rat serum, 5% 
normal mouse serum, 5% normal rabbit serum, 10 μg/ml 
2.4g2 anti-FcR and 0.2% NaN3 in DPBS) on ice for 30 
minutes. Cells were then stained with various antibodies 
(see the list of antibodies in Supplemental Table 1A) on ice 
for 30 minutes and washed with FACS buffer. For blood 
analysis, blood samples were taken via tail vein bleeding, 
lysed with RBC lysis buffer (Biolegend, San Diego, CA), 
washed with FACS buffer, counted with a hemocytometer, 
and stained using the same protocol before analyzing. The 
list of antibodies is included in Table S1A. All data were 
collected on a LSR II Fortessa (BD Biosciences, San Jose, 
CA) and analyzed using FlowJo 9 software (Tree Star Inc., 
Ashland, OR).
For tumor cell sorting, brains were digested for 
15 minutes (GBM) or 30 minutes (naïve brains, without 
cerebellum) at 37°C in 5 ml of freshly prepared digestion 
solution (0.94 mg/ml papain (Worthington), 0.48 mM 
EDTA, 0.18 mg/ml N-acetyl-L-cysteine and 0.06mg/ml 
DNase I (Sigma-Aldrich, St. Louis, MO) diluted in Earl’s 
Balanced Salt Solution (EBSS)). Two ml of Ovomucoid 
solution (0.71 mg/ml dissolved in Neural Stem Cell (NSC) 
Basal Medium) was used to terminate the digestion. Cells 
were washed in NSC Basal Medium and passed through a 
40 μm cell strainer before sorting.
For immune cell sorting, cells were further 
washed with HBSS, resuspended in 30% Percoll solution 
(prepared with RPMI medium with 1% FBS), and placed 
under a HBSS aqua phase. Cells were centrifuged (low 
acceleration and no brake) at 950xg for 20 minutes at 
4°C. Pelleted cells were washed with FACS buffer before 
sorting. Staining was performed as described above.
RNA extraction and Real-time PCR
Tumors and naïve brains from tumor-bearing 
or control animals were removed after transcardiac 
perfusion with ice-cold Ringer’s solution and snap frozen 
and stored at -80°C until RNA extraction. RNA from 
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tumor tissue or freshly sorted cells was extracted using 
an RNeasy Plus Mini kit (QIAGEN, Valencia, CA) and 
from naïve brains using an RNeasy Lipid Tissue Mini kit 
(QIAGEN, Valencia, CA) according to the manufacturer’s 
instructions.
RNA concentrations were measured with a 
NanoDrop spectrophotometer and samples were stored 
at -80ºC. cDNA was synthesized from total RNA using 
the SuperScript III First-Strand Synthesis System (Life 
Technologies, Grand Island, NY). Real-time PCR 
(quantitative PCR) was performed using a FastStart SYBR 
Green Master mix (Roche Applied Science, Mannheim, 
Germany) according to manufacturer’s instructions. 
Amplification was performed in the Applied Biosystems 
7500 Fast Real-Time PCR System (Life Technologies). 
Primer sequences are shown in Supplemental Table 1B. 
β-actin was used as an internal control and the ΔΔCT 
method was used to calculate changes in fold expression. 
Tumor dissociation and primary cell cultures
PDGF-driven tumors were dissociated as described 
in the flow cytometry section above. Briefly, tumors were 
dissected and collected in basal neural stem cell culture 
medium. Five ml of digestion solution per tumor was 
used to digest tissues. Cells were consecutively washed 
and resuspended to obtain a single cell suspension. For 
tumorsphere cultures, cells were seeded at 50x104 cells/
ml and grown in mouse neurosphere medium (Stem Cell 
Technologies, Vancouver, Canada) supplemented with 
10ng/ml hEGF, 20 ng/ml basic-hFGF, 1 mg/ml Heparin, 
and NSC Proliferation Supplements. Fresh medium was 
added to the cultures every 48 hours before treatment. For 
primary monolayer cultures, cells were cultured in high 
glucose DMEM supplemented with 10% FBS; medium 
was changed every 2 days. For IL-1β treatment and 
MTT assays, cells were grown as adherent monolayer 
cultures on Geltrex-coated tissue culture plasticware 
(Life Technologies, Grand Island, NY), which were 
prepared according to manufacturer’s instructions. 
This approach for in vitro experiments provided better-
controlled and more reproducible results compared to 
when cells are grown as neurospheres. When GSCs are 
grown as neurospheres, the size of the neurospheres is 
highly variable and can greatly impact the availability of 
exogenous IL1β for cells in the core of spheres. It becomes 
especially crucial when time points for collecting samples 
after adding exogenous IL1β are short. 
Organotypic slice cultures
P14-P16 Cx3cr1GFP/GFP, Cx3cr1GFP/+, and B6 
littermate mice were decapitated and brains were removed 
and placed in ice-cold phosphate-buffered saline (PBS) 
under sterile conditions. The forebrain was dissected 
from the brainstem and glued (using cyanoacrylate 
glue) onto a glass block and cut in the coronal plane into 
250 μm sections with a vibratome (Microm HM 650 V, 
Thermo Scientific, Waltham, MA). Brain slices were 
transferred onto 0.4 μm polycarbonate membranes in 
the upper chamber of a transwell tissue insert (Falcon 
model 3090, Becton Dickinson, Franklin Lakes, NJ), 
which was inserted into a 6-well plate (Falcon model 
3502, Becton Dickinson, Franklin Lakes, NJ). Thereafter, 
brain slices were incubated in 1 ml of culture medium 
per well containing DMEM supplemented with 10% 
heat-inactivated fetal bovine serum (Atlanta Biological, 
Norcross, GA), 0.2 mM glutamine, 100 U/ml penicillin, 
and 100 mg/ml streptomycin (medium-1). After overnight 
equilibration of the brain slices in medium-1, this 
was exchanged for cultivation medium (medium-2). 
Medium-2 contained 25% heat-inactivated horse serum, 
50 mM sodium bicarbonate, 2% glutamine, 25% Hank’s 
balanced salt solution, 1 mg/ml insulin (all from Life 
Technologies, Grand Island, NY), 2.46 mg/ml glucose 
(Braun Melsungen, Germany), 0.8 mg/ml vitamin C 
(Sigma-Aldrich, St. Louis, MO), 100 U/ml penicillin, 100 
mg/ml streptomycin (Sigma-Aldrich, St. Louis, MO), and 
5 mM Tris in DMEM (Life Technologies, Grand Island, 
NY).
Tumor cell injections into cultured brain slices
One day after cutting, 5000 cultured RCAS-
PDGFB-SV40-RFP tumor cells in a volume of 0.1µl were 
injected into the slices using a Hamilton syringe mounted 
to a micromanipulator. An injection canal was formed that 
reached 150 µm deep into the 250 µm-thick slice. The 
needle was then retracted by 50µm, leaving an injection 
cavity of approximately 50µm. The cell suspension 
was slowly injected over 30 seconds and subsequently 
the syringe was slowly pulled out in 10µm incremental 
steps over 60 seconds. To ensure identical experimental 
conditions, gliomas were always inoculated into the same 
area. Tumor sizes were determined 6 and 12 days post-
injection by fluorescence microscopy (Axiovert 135, 
Carl Zeiss, Jena Germany) and the fluorescent area was 
evaluated with Fiji ImageJ. 
Re-cutting of cultured slices
For analysis of microglial invasion into tumor areas, 
slices were fixed 4 days post-injection of tumor cells with 
4% PFA for 1 hour and subsequently stored in 30% sucrose 
until further use. Fixed slices were mounted on plain-
cut blocks of Tissue-Tek O.C.T. (Sakura, Tokyo, Japan), 
covered with more Tissue-Tek O.C.T., and subsequently 
cut into 10µm sections using a Leica CM1950 Cryostat 
(Leica Microsystems, Wetzlar, Germany). Confocal 
images were prepared using a Leica TCS SPE confocal 
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microscope (Leica Microsystems) and evaluated using 
Adobe Photoshop and Fiji ImageJ. 
Immunoblot analysis
Antibody against actin was purchased from 
Santa Cruz Biotechnologies, Santa Cruz, CA. Cells 
were harvested and lysed in a Triton-containing lysis 
buffer (0.5% Triton X-100, 20mM HEPES (pH 7.4), 
150 mM NaCl, 12.5 mM β-glycerophosphate, 1.5 mM 
MgCl2, 10 mM NaF, 2 mM dithiothreitol, 1 mM sodium 
orthovanadate, 2mM EGTA, 1mM phenylmethylsulfonyl 
fluoride and complete protease inhibitor cocktail from 
Roche). Cell lysates were then separated by 10% 
SDS-PAGE, transferred to Immobilon-P membranes 
(Millipore), and subjected to immunoblotting. Antibodies 
against phosphorylated JNK, p38 (Thr180/Tyr182), 
and Erk1/2 (Thr202/Tyr204) were purchased from Cell 
Signaling, Danvers, MA. Quantification of western 
blots was performed using ImageJ. Intensity values for 
phosphorylated proteins were normalized per totals, 
which were first normalized per actin of each blot. Four 
independent primary mouse tumor-derived GSCs were 
used for western blots. 
Limiting Dilution Assay (LDA)
LDA was performed in 96-well plates. Briefly, 
dissociated cells were seeded at a range of 1–100 cells 
per well with or without bFGF and EGF and then 400 pM 
IL1β was added every 3 days. Cells were incubated at 
37°C for 2 weeks. At the time of quantification, each well 
was examined for the formation of tumor spheres. Stem 
cell frequency and p-values were calculated using a web-
based tool “ELDA” (extreme limiting dilution analysis), 
which is available on the Walter and Eliza Hall Institute 
of Medical Research web site (http://bioinf.wehi.edu.au/
software/elda/). 
The 827 and GSC7-11 cells were generously 
provided by Drs. Jeognwu Lee and Erik Sulman. Both cell 
lines display characteristics of the Proneural subtype, as 
revealed by RNA-seq, by centroid analysis (827) [31], and 
by microarray analysis using the unsupervised algorithm 
(GSC7-11) [32]. GSCs were cultured in neurobasal media 
with N2 and B27 supplements (0.5× each; Invitrogen) and 
human recombinant bFGF and EGF (25 ng/ml each; R&D 
Systems) (NBE condition).
MTT assay
Cells from murine GBM tissues were cultured in 
10% FBS containing medium (DMEM) or neural stem 
cell medium. 10k cells were seeded into each well in a 
96-well plate. 24 hours later, medium was changed to 1% 
FBS DMEM or neural stem cell medium without bFGF 
or EGF. Cells were starved for 16h before IL1β treatment, 
followed by 24 hours of 100pM of IL1β (401-ML-005/
CF R&D, Minneapolis, MN) diluted in 1% FBS DMEM 
medium or complete neural stem cell medium (with EGF 
and FGF) for FBS cultures and neural stem cell cultures, 
respectively. MTT assays (TOX1-1KT) were performed 
according to the manufacturer’s instructions (Sigma-
Aldrich, St. Louis, MO). 
Side population analysis (SP) by FACS
SP analysis was performed as described previously. 
Briefly, after tumor dissociation, cells were incubated at 
37ºC with (controls) or without (samples) Fumitremorgin 
C (Sigma-Aldrich, St. Louis, MO), followed by staining 
with Dyecycle Violet (Life Technologies, Grand Island, 
NY) at 37ºC for 90 minutes. Cells were washed and 
stained with propidium iodide (PI) before analyzing. 
Signals were excited by the violet laser (407 nm) on LSR 
Fortessa. DCV-red and DCV-blue signals were collected 
through 670/30 nm and 450/50 nm filters, respectively. For 
in vitro experiments, cells were incubated with or without 
100 pM IL1β, collected, and analyzed for SP as described 
above. 
TCGA analysis
Expression values and patients survival data for 
each gene of interest were obtained from the MSKCC 
computational biology cancer genomics portal-cBioPortal 
(http://www.cbioportal.org/cgx/index.do) which has 
annotated TCGA data [44, 45]. (Study: Glioblastoma 
multiforme, TCGA Provisional, mRNA Expression 
z-Scores (microarray), accessed in June 2014. Tumor 
subtype classification was previously described [3].
Statistical analysis
Graphs were created using GraphPad Prism 6 
(GraphPad Software Inc., La Jolla, CA) and were analyzed 
using an unpaired parametric two-tailed t-test, assuming 
equal standard deviations. One-way ANOVA was used 
in experiments having more than one group to compare 
to controls. Test details are included in appropriate figure 
legends; (*) P < 0.05; (**) P < 0.01; (***) P < 0.001; (no 
asterisks) not significant.
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